
    
      ADU-CL-17 is a first-in-human, open-label, multicenter, dose-escalation study designed to
      evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of ADU-1604, an
      anti-CTLA-4 monoclonal antibody, and explore initial clinical activity in adults with
      metastatic melanoma. The primary objective of the study is to determine the Recommended Phase
      2 Dose (RP2D) of ADU-1604 administered by IV infusion once every 3 weeks for 4 doses.

      The study will be conducted in two parts: Dose Escalation followed by Dose Confirmation.
    
  